Genetic factors are recognized to contribute to common gastrointestinal (GI) diseases such as gastro-12 oesophageal reflux disease (GORD), peptic ulcer disease (PUD), irritable bowel syndrome (IBS) and 13 inflammatory bowel disease (IBD). We conducted genome-wide association analyses based on 456,414 14 individuals and identified 27 independent and significant loci for GORD, PUD and IBS, including SNPs 15 associated with PUD at or near genes MUC1, FUT2, PSCA and CCKBR, for which there are previously 16 established roles in Helicobacter pylori infection, response to counteract infection-related damage, gastric acid 17 secretion and gastrointestinal motility. Post-GWAS analyses implicate putative functional links between the 18 nervous system and gastrointestinal tract for GORD, PUD and IBS, including the central nervous system, the 19 enteric nervous system and their connection. Mendelian Randomisation analyses imply potentially bi-20 directional causality (the risk of GORD in liability to major depression and the risk of major depression in 21 liability to GORD) or pleiotropic effect between them. A stronger genetic similarity among GORD, PUD and IBS 22 than between these disorders and IBD is reported. These findings advance understanding the role of genetic 23 variants in the etiology of GORD, PUD and IBS and add biological insights into the link between the nervous 24 system and the gastrointestinal tract. 25 1
Introduction
IBS+M and SNPs associated with IBD are in Table S3 . The GERA cohort data were available as a replication 23 sample for PUD (1,004 cases, 60,843 controls). Of the four genome-wide significant SNPs for PUD in UKB, all 24 have very similar effect size estimates in GERA (Table S4 ) but only rs681343 is formally significant (P = 5.0E-4). 25 Many of the SNPs reported in Table 2 are novel. Genes around these SNPs have biological support for their 26 mechanistic involvement in corresponding diseases, even known therapeutic-effect mediating target genes for 27 the treatment of corresponding diseases. Notable results are presented in the discussion section. Among 23 28 IBD-associated SNPs in UKB, 21 have been previously linked with inflammatory bowel diseases (Table S3 ). 1 Figure 2 shows Manhattan plots for GORD, PUD, GP+M and IBS+M and Figure S2 shows Manhattan plots for 2 the other two phenotypes. Quantile-Quantile (Q-Q) plots of all the variants analysed in UKB are provided in 3 Figure S3 for the six phenotypes. Regional visualisation plots of the 50 independent variants are in 4
Supplementary Data 1. Detailed pleiotropy results derived from GWAS Catalog 29 are provided in 5
Supplementary Data 2. 6 SNP-based heritability and genetic correlation of the six digestion phenotypes 7 LDSC 30 SNP-based heritability (ℎ "#$ % ) estimates on the liability scale were all significantly different from zero: 8 GORD 0.08 (SE = 0.005), PUD 0.05 (SE = 0.008), GP+M 0.10 (SE = 0.004), IBS 0.06 (SE = 0.008), IBS+M 0.07 (SE = 9 0.008) and IBD 0.12 (SE = 0.017) ( Figure 3A , Table S5 ). The SNP-based genetic correlations (rg) between GORD 10 and PUD is 0.65 (SE = 0.06, PH0:rg=0 = 6.5E-28, phenotypic correlation (rp) = 0.10), similar to the rg estimate for 11 GORD and IBS (0.61, SE = 0.06, PH0:rg=0 = 1.5E-26, rp = 0.08). The rg between PUD and IBS is 0.48 (SE = 0.10, 12 PH0:rg=0 = 8.0E-7, rp = 0.03) ( Table S6) , while the rg between IBD and each of GORD, PUD, GP+M, IBS and IBD are 13 not statistically significantly different from zero after Bonferroni correction (Figure 3B) . In sensitivity analyses, 14 all individuals with more than one GI diagnosis were excluded ( Figure S4A) . As expected, the ℎ "#$ % estimates 15 were lower but still significantly different from zero (Figure S4B) . GORD, PUD and IBS are significantly 16 genetically correlated while none of them showed statistically significant rg with IBD ( Figure S4C) . Detailed 17 results of sensitivity analyses are discussed in Supplementary Note 1 with the corresponding data presented in 18 Table S7 and Figure S4 . 19 The rg between each of the six phenotypes and six published psychiatric traits [31] [32] [33] [34] [35] [36] and 252 other traits 20 from LD Hub 37 (Table S8 and Supplementary Data 3, respectively) included 27, 20, 45, 11, 14 and 3 significant 21 correlations for GORD, PUD, GP+M, IBS, IBS+M and IBD, respectively, after Bonferroni correction (P < 3.2E-5). 22 Figure 3B shows the rg between each of the six phenotypes and selected traits from the 258 traits. 23 Interestingly, we observed significant rg between three digestion phenotypes and depressive symptoms 38 24 (GORD (0.46, SE = 0.05, PH0:rg=0 = 1.7E-21), PUD (0.52, SE = 0.09, PH0:rg=0 = 1.2E-9), IBS (0.52, SE = 0.07, PH0:rg=0 = 25 1.5E-12)). IBS was significantly genetically correlated with major depression (MD) 39 (0.43, SE = 0.10, PH0:rg=0 = 26 2.1E-5)). We also observed significant rg between IBS and neuroticism 40 (0.50, SE = 0.06, PH0:rg=0 = 1. 1E-18) , and 27 between GORD and neuroticism 40 (0.35, SE = 0.04, PH0:rg=0 = 3.6E-15). Attention deficit hyperactivity disorder 28 standard deviation (SD) in liability to MD (Figure 4A) . The point estimates for the reverse causality analyses 23 were smaller, but it is not possible to make strong statements about the significance of the estimates because 24 we needed to relax the significance threshold imposed to achieve a sufficient number of SNP instruments; 25 these analyses should be revisited in when more genome-wide significant SNPs are identified. (Figure 4A , 26   Table S15 ) . 27 Genetic risk score (GRS) prediction 28 infection 17 . From published data, we also found that allele A of SNP rs2976388 is associated with increased 1 PSCA expression (beQTL = 0.73, PeQTL = 8.8E-41), and through SMR analysis, the expression of PSCA decreased 2 risk for PUD (bSMR= -0.12, PSMR = 4.8E-9). Decreased PSCA expression has been reported following Helicobacter 3 pylori infection 53 , indicating negative regulation of PSCA expression by Helicobacter pylori infection. Other data 4 sets recorded for Helicobacter pylori infection status are needed to explore this proposed relationship. Two 5 other novel PUD-associated SNPs may also relate to genetic risk to Helicobacter pylori infection: rs147048677 6 (P = 1.6E-11) is a synonymous variant in the MUC1 gene. A mouse model study 54 has shown that Muc1 limits 7
Helicobacter pylori colonization of gastric mucosa. rs681343, which we found to be statistically significant in 8 both UKB discovery and GERA replication GWAS for PUD, is located in the FUT2 gene and this gene has also 9 been implicated in susceptibility to Helicobacter pylori infection 55 in humans. A novel PUD-associated SNP, 10 rs10500661 (P= 6.7E-10) is located in 7.2kb upstream of CCKBR (cholecystokinin B receptor) and this gene 11 encodes a G-protein coupled receptor for both gastrin and cholecystokinin, regulatory peptides of the brain 12 and gastrointestinal tract 56 . This gene, as shown in the GTEx 42 portal 13 (https://gtexportal.org/home/gene/CCKBR), is highly expressed in the brain frontal cortex (Brodmann Area 14 (BA) 9) and stomach. Moreover, this gene is a therapeutic-effect target gene for proglumide (ATC code: 15 A02BX06) to treat peptic ulcer, of which the mechanism is to inhibit gastrointestinal motility and reduce 16 gastric acid secretions. In addition to these findings, itriglumide, an antagonist for the CCKBR protein, has been 17 investigated as a potential treatment for anxiety and panic disorders 57 . 18 For GP+M, two of the significantly associated SNPs, rs6809836 and rs12462498, have been previously 19 linked to Barrett's esophagus and esophageal adenocarcinoma 58, 59 (Table 2) . Another GORD-associated SNP, 20 rs10891491, is located in the NCAM1, TTC12 and DRD2 gene region which has been linked to depressive 21 symptoms. DRD2 is therapeutic target gene for atypical antipsychotics, such as ziprasidone (ATC code: 22 N05AE04) 60 . Blocking dopamine D2 receptors encoded by this gene in the chemoreceptor trigger zone relieves 23 nausea and in the gastrointestinal tract increases motility 61 . A previous study reported that rs10512344 is the 24 only one SNP genome-wide significantly associated (P = 3.6E-8) with IBS using UKB data 20 . Both the IBS (lead 25 SNP: rs112243849, P = 7.5E-8) and IBS + M (lead SNP: rs7861675, P = 1.2E-7) phenotypes in our study 26 reconfirmed the association between this locus and IBS at the genome-wide suggestive level. A detailed 27 comparison with this study is provided in Supplementary Note 3. 28
Third, we provide direct genetic evidence that IBD is etiologically different to the other digestion 1 phenotypes as illustrated by high genetic correlations among GORD, PUD, IBS, which all show low genetic 2 correlations with IBD ( Figure 3B) . Both GORD and PUD are acid-related diseases; their high genetic correlation 3 (rg = 0.65, PH0:rg=0 = 6.5E-28) motivated the combination of GORD and PUD with medication taking cases. The 4 high genetic relationship between GORD and IBS is not unexpected given that a highly comorbid relationship 5 has been previously reported 62 . Orthogonal evidence for genetic differences between IBD and the other 6 digestion phenotypes was provided by the partitioned SNP-based heritability analyses, which showed 7 enrichment of GP+M-associated SNPs in genes expressed in the BA9 region of the brain cortex while those for 8 IBD are enriched in blood and immune related tissues. Gene set enrichment analysis showed GP+M associated 9
SNPs are enriched in neuron-related gene sets. We note that a limitation of our brain enrichment analysis is 10 that our conclusions are limited by the availability of tissue specific gene expression data. The GTEx database 11 does not report gene expression data for multiple cortical regions, so specificity to BA9 or frontal cortex (over 12 and above other cortical regions) is not established. As discussed by Finucane et al. 41 , it is not possible to draw 13 strong conclusions about the most likely causal tissue or cell type as only a subset of cell types are tested, we 14 can only say tissues with similar gene expression profiles to BA9 of brain or BA9 itself may be relevant to 15 GP+M. Given the non-availability of gene expression data from other human tissues, such as sympathetic, 16 parasympathetic (vagus nerve) 23 and enteric nervous system 22, 24 , we cannot conduct key hypothesis based 17 enrichment analyses. However, despite these limitations, our findings indicate that a genetic contribution to 18 GP+M may highlight the potential link between the nervous system and oesophagus, stomach and duodenum 19 though there is likely not just one causal tissue or cell type. Historically, vagotomy was used commonly to 20 manage peptic ulcer diseases, as vagal stimulation promotes acid secretion 63 (now successfully treated by H2 21 receptor agonists), indicating the clinical importance of the link between the nervous system and 22 gastrointestinal tract. We note that we did observe a significant genetic correlation between IBS+M and 23 published IBD European GWAS summary statistics 64 (rg = 0.23, SE = 0.05, PH0:rg=0 = 1.6E-5, the rg between IBS 24 and IBD was 0.21, SE = 0.05, PH0:rg=0 = 2.0E-4). However, this relative lower genetic correlation suggests that IBD 25 is etiologically different from IBS. 26
Fourth, we conducted Mendelian Randomisation (MR) to investigate if this methodology provides 27 evidence of a causal relationship between major depression and GI disorder phenotypes. The association 28 disciplines are needed to understand the connection. While a causal relationship cannot be confirmed 23 between major depression and digestion related disorders, consideration of clinical implications of a possible 24 relationship is justified. When treating patients with MD, awareness of the digestion symptoms for GORD 25 could help to decide if further interventions are needed. Also, these results may provide clues for screening 26 psychological factors in GORD patients. Previous study 72 shows that GORD patients who are also comorbid 27 with psychologic distress are associated with more severe symptoms at baseline and more residual symptoms 28 after PPI treatment. In those patients, treatment for the underlying psychological distress might improve the 1 PPI response 73 . 2 Despite these interesting findings, our study has several limitations. First, the phenotype of GORD, 3 PUD and IBS was a combination of self-reported illness, medication-use and clinical diagnosis record. There is a 4 potential influence regarding self-reported accuracy and misdiagnosis. Given the existent co-reporting of some 5 diagnoses, we conducted sensitivity analyses in which individuals recorded with more than one diagnosis were 6 excluded, but these analyses did not impact our conclusions. Importantly, we note that the GWAS results from 7 IBD derived from the UKB were highly consistent with results from published GWAS. Second, our study is 8 conducted in the UK Biobank cohort, which while a large population study has recognised volunteer bias 74 . 9
Third, we do not have replication data sets for GORD, GP+M and IBS+M genome-wide significant SNPs. Fourth, 10 we do not have the Helicobacter pylori infection status and microbiome data in UKB, thus additional analyses 11 on these factors cannot be further explored. Fifth, we note a recent a meta-analysis GWAS study for GORD 75 12 using UKB cohort, however, there are differences with our study. Our study focus is on GWAS of multiple 13 digestion disorders, not limited to GORD. Our study addresses the link between the digestive tract and nervous 14 system while they focus on GORD-associated loci that also associated with Barrett's oesophagus and 15 oesophageal adenocarcinoma. We also explore the comorbidity relationship within digestion disorders and 16 between each of digestion disorders with depression in UKB. 17
In summary, the study identified 27, mostly novel, independent SNPs associated with different 18 digestion disorders, including SNPs at or near MUC1, FUT2, PSCA and CCKBR genes associated with peptic ulcer 19 disease, for which previously established roles of these genes in Helicobacter pylori infection, response to 20 counteract infection-related damage and gastric secretion support their involvement. Post-GWAS analyses 21 highlighted the link between nervous system and the gastrointestinal tract, which may add biological insight 22
into nervous system-gastrointestinal tract links and aetiology of relevant diseases. In addition to this, 23
Mendelian Randomisation analyses imply potentially bi-directional causality (the risk of GORD in liability to 24 major depression and the risk of major depression in liability to GORD) or pleiotropic effect between them. 25
Taken together, our findings demonstrate the role of genetic variants in the aetiology of common digestion 26 disorders and the link between depression and GORD. 27 
Methods

6
UK Biobank genotyping and quality control 7 The United Kingdom Biobank (UKB) cohort is a population-based volunteer longitudinal cohort consisting of 8 ~500,000 individuals recruited at 22 centres across the United Kingdom 76 . Genotype data from these 9 individuals were imputed using the Haplotype Reference Consortium (HRC) and UK10K as the reference 10 sample. A European ancestry subset (456,414 individuals, including 348,501 unrelated individuals) was 11 identified by projecting the UKB participants onto the 1000 Genome Project principal components 12
coordinates. Genotype probabilities were converted to hard-call genotypes using PLINK2 77 (hard-call 0.1) and 13 single nucleotide polymorphisms (SNPs) with minor allele count < 5, Hardy-Weinberg equilibrium test P value < 14 1.0E-5, missing genotype rate > 0.05, or imputation accuracy (Info) score < 0.3 were excluded. 15
Phenotype definition 16 The UKB phenotypes used in analyses were derived from two categories: one is disease-diagnoses from the 17 combination of self-reported non-cancer illness code (UKB data field 20002) and ICD10 codes from hospital 18 admission records (UKB data fields: 41202 and 41204). The other category is medication-taking based on 19 treatment/medication code (UKB data field 20003; see also Table S2 ). For the GORD disease-diagnoses 20 phenotype (39,851 cases and 416,563 controls), participants were classified as cases if they had either a self-21 reported (code: 1138) or ICD10 (code: K210 and K219) record for GORD. The remaining individuals were 22 assigned as controls. PUD disease-diagnoses cases are a combination of stomach ulcer cases (self-reported 23 code: 1142, ICD10 code: K250-K257 and K259), duodenal ulcer cases (self-reported code: 1457, ICD10 code: 24 K260-K267 and K269) and other site peptic ulcer cases (self-reported code: 1400, ICD10 code: K270-K277 and 25 K279). The remaining individuals were PUD controls. There were 12,226 cases and 444,188 controls for PUD. In 26 clinical practice, medications for PUD also have a therapeutic effect on GORD. Thus, we first identified 54,541 27 individuals taking medications that are mainly considered medications for GORD/PUD (Table S2 ) and further 28 combined these medication-taking cases with diseases-diagnoses cases for GORD and PUD, leaving a total of 29
We performed case-control GWAS analyses using BOLT-LMM 84 with sex, age and 20 ancestry principal 1 components (PCs) fitted as covariates. 543,919 SNPs generated by LD pruning (r 2 < 0.9) from Hapmap3 SNPs 2 were used to control for population structure and polygenic effects, including genetic relatedness between 3 individuals. The effect size (b) from BOLT-LMM on the observed 0-1 scale were transformed to odds ratio (OR) 4 using the following equation 85 
, where k is the proportion of sample that are cases, and r 5 is the allele frequency in the full UKB European cohort. The standard error (s.e.) for OR were then calculated 6 based on the OR and P value from the initial GWAS using the formula s. e. = 6 78(9:) ; <= > ? @ A 6. A total of 8,546,066 SNPs 7 with minor allele frequency (MAF) > 0.01 were analysed. Quasi-independent trait-associated regions were 8 generated through linkage disequilibrium (LD) clumping retaining the most associated SNP (lead SNP) in each 9 region (PLINK (v1.90b) 77 --clump-p1 5.0E-8 --clump-p2 5.0E-8 --clump-r2 0.01 --clump-kb 1000). In addition to 10 the genome-wide significant SNPs identified through BOLT-LMM, the genotype data (8,546,066 SNPs with 11 MAF > 0.01) of 348,501 unrelated European individuals were used to provide a LD reference. Due to the 12 complexity of major histocompatibility complex (MHC) region (25Mb -34Mb), only the most significant SNP 13 across that region was reported. Regional visualisation plots were produced using LocusZoom 86 . The genomic 14 inflation factor ( GC) was also reported for each phenotype. We used the GERA 79 cohort PUD GWAS summary 15 statistics 48 for a validation look-up of the UKB PUD genome-wide significant SNPs. We also conducted 16 pleiotropy (SNP associated with multiple traits) analysis. Briefly, we downloaded published GWAS associations 17 from the GWAS Catalog 29 on July 9 2019. For each of GORD, PUD, GP+M and IBS+M associated SNPs in our 18 study (index SNP), we first selected SNPs from the GWAS Catalog within a ±1,000kb window size of the index 19 SNP. We then selected the GWAS Catalog SNPs significantly associated (P < 5.0E-8) with either mental health-20 related traits or digestive diseases. We reported as a pleiotropic association if selected GWAS Catalog SNPs are 21 in LD (r 2 > 0.1) with the index SNP. Similarly, for IBD-associated SNPs in our study, we checked whether 22 significant association (P < 5.0E-8) have been reported for inflammatory bowel diseases (including the 23 subtypes) using the downloaded GWAS Catalog data. 24 25 Linkage Disequilibrium Score regression (LDSC) 30 was used to estimate SNP-based heritability (ℎ "#$ % ) from the 26 GWAS summary statistics. The ℎ "#$ % estimated on the observed scale were transformed to the liability scale 27 taking the sample lifetime risk (proportion of sample that are cases) as the disease lifetime risk estimates. The 28 summary statistics for each phenotype were filtered using the LDSC default file, w_hm3.snplist, with the 1 default LD scores computed using 1000 Genomes European data (eur_w_ld_chr) as a reference. Genetic 2 correlations (rg) between any two of the six UKB digestion phenotypes or each of the six phenotypes and six 3 published psychiatric traits (attention deficit/hyperactivity disorder (ADHD) 31 , schizophrenia (SCZ) 32 , anxiety 4 disorder 33 , posttraumatic stress disorder (PTSD) 34 , bipolar disorder (BIP) 35 and autism spectrum disorder 5 (ASD) 36 ) were calculated using bivariate LDSC 87 . The rg were also calculated between each of the six digestion 6 phenotypes and 252 other traits using LD Hub 37 . As sensitivity analyses, we repeated analyses after excluding 7 any individual recorded to have more than one disorder. Although removal of these individuals could make 8 estimates of SNP-based heritability difficult to interpret, genetic correlations are more robust to such 9 ascertainment 67 . 10
SNP-based heritability and genetic correlations of the six digestion phenotypes
Linking GWAS findings to gene expression 11 Following the estimation of ℎ "#$ % , we partitioned the heritability by genomic features 88 . Briefly, in this 12 method 88 , genetic variants are assigned into 53 functional categories using 24 publicly available annotation 13
data sets, such as UCSC coding, UTRs, promoter and intronic regions 89 , conserved regions 90 and functional 14 genomic annotations constructed using ENCODE 91 and Roadmap Epigenomics Consortium data 92 . The method 15 evaluates the contribution of each functional category to the overall ℎ "#$ % of a trait. A category is enriched for 16 ℎ "#$ % if the variants with high LD to that category have elevated c 2 statistics, compared to the expectation given 17 the number of SNPs in the category. In another analysis, genetic variants were annotated to histone marks 18 (H3K4me1, H3K4me3, H3K9ac and H3K27ac) by cell type specific classes and these annotations were allocated 19 to 10 groups: adrenal and pancreas, central nervous system (CNS), cardiovascular, connective and bone, 20
gastrointestinal, immune and hematopoietic, kidney, liver, skeletal muscle and other. We tested the 21 enrichment of ℎ "#$ % in tissues relevant to the 6 digestion phenotypes: the adrenal and pancreas, 22
gastrointestinal, immune and hematopoietic and liver cell types. We also considered the CNS given the high rg 23
between the 5 of the six digestion phenotypes and depressive symptoms. We also used LDSC specific 24 expressed genes (SEG) 41 analysis to test the enrichment of ℎ "#$ % through gene expression derived cell-type 25 specific annotations. First, given the strong contribution to GP+M ℎ "#$ % from the CNS and to IBD ℎ "#$ % from the 26 immune cell group, LDSC-SEG 41 was applied to test the enrichment of ℎ "#$ % in 205 different tissues (53 from  27 GTEx 42 and 152 from Franke lab 43, 44 ). Second, given the observation that GORD, GP+M and IBS+M ℎ "#$ % were 28 enriched in the CNS, we also applied LDSC SEG to test the enrichment of ℎ "#$ % for GORD, GP+M and IBS+M in 13 1 brain regions using the multiple brain regions available in the GTEx study (https://gtexportal.org/home) data 42 2 to identify specific brain regions implicated by the GWAS results for the three phenotypes. Bonferroni 3 correction was used to account for multiple testing. We checked eQTL (expression quantitative trait loci, i.e. 4
SNPs associated gene expression in different tissues) status for each genome-wide significant SNP using GTEx 42 5 results for gastrointestinal tissue and brain tissues. Summary-data-based Mendelian Randomisation (SMR) 48 6 was used to provide evidence for likely causal relationship between the trait-associated SNPs and gene 7 expression. We used eQTLGen 93 whole blood eQTL data since this is the largest eQTL data set and many eQTLs 8 are shared across tissues 94 . To capture more tissue specific eQTL, we used GTEx 42 eQTL data from 6 tissues: 9 oesophagus-gastroesophageal junction, oesophagus mucosa, oesophagus muscularis, stomach, colon sigmoid, 10 colon transverse tissue. We also used GTEx eQTL data from frontal cortex (BA9) tissue for GORD, PUD, GP+M, 11 IBS and IBS+M given ℎ "#$ % enrichment results. The Bonferroni corrected significance threshold was 12 0.05/155,059, where 155,059 is the number of total genes tested in SMR analyses. Because of its complexity, 13
we do not report results of the MHC region (25Mb -34Mb) 48 . 14 15 MAGMA (v1.06) 46 (Multi-marker Analysis of GenoMic Annotation) was used to test for gene-based association 16 based on the SNP association results of the six digestion phenotypes. Gene length boundaries were defined as 17 35 kilobase (kb) upstream and 10 kb downstream from start and stop site, respectively, to include regulatory 18 elements. The NCBI 37.3 build was used to assign the genetic variants to each gene. SNPs with MAF > 0.01 19 from 10,000 randomly sampled unrelated UKB European-ancestry individuals were used to provide a LD 20 reference. A total of 18,402 genes were assessed for an association with each of the six digestion phenotypes 21
Gene-based and gene-set enrichment analyses
with Bonferroni correction used to determine significance (α = 0.05/18402 , P < 2.7E-6). We used the results 22 obtained from gene-based analysis, together with curated gene sets (c2.all) and gene ontology sets (c5.bp, 23 c5.cc, c5.mf) from MSigDB (v5.2) 95,96 to conduct gene-set enrichment analyses. Competitive test P value for 24 each gene set, as implemented in MAGMA, were computed taking gene size, density, minor allele count and 25 gene-gene correlation into consideration 46 . False discovery rate (FDR)-adjusted P values for biological 26 pathways for each of the six digestion phenotypes were generated using Benjamini and Hochberg's method 97 27 to account for multiple testing. 28 1
We applied the Generalised Summary-data-based Mendelian Randomisation (GSMR) 48 method to explore the 2 potentially causal effect of MD as an exposure on the six UKB digestion phenotypes as outcome traits (defined 3 as forward direction). GSMR uses summary-level data to test for causal associations between a putative risk 4 factor (exposure) and an outcome trait. Independent genome-wide significant SNPs from the MD GWAS 5 (excluding UKB cohort) 49 were used as the Mendelian Randomisation (MR) exposure instrument variables. The 6 HEIDI outlier test 48 was used to remove outlier pleiotropic genetic instruments associated with both exposure 7 phenotype and outcome phenotype from the analysis. We also conducted reverse causation analysis (i.e. 8
testing the opposite hypothesis that the six digestion phenotypes cause MD). However, GSMR guidelines 9 advise the use of at least 10 independent lead SNPs as genetic instruments to achieve robust results. In order 10 to test the effect of GORD (5 SNPs with P < 5.0E-8), PUD (4 SNPs), IBS (0 SNP) and IBS+M (3 SNPs) on MD, we 11 relaxed the significance threshold to allow for at least 10 SNPs for each of the four phenotypes. The other 12 parameters were set to software defaults. For comparison, we also conducted IVW-MR 98 , MR-Egger 99 , 13 weighted median-MR 100 and MR-PRESSO 101 analyses following the STROBE-MR guideline 102 . 14 Genetic risk score (GRS) prediction 15 We used MD GWAS summary statistics 49 (European ancestry, excluding UKB cohort) as discovery data to 16 predict GP+M risk (risk for GORD, PUD and likelihood for taking GORD, PUD drugs). The MD data SNPs were 17 matched with the GP+M SNPs (7,156,547 SNPs), then LD pruned and "clumped", discarding variants within 18 1,000kb of, and in r 2 ³ 0.1 with, another (more significant) marker using SNPs with MAF > 0.01 from 10,000 19 random sampled unrelated UKB European-ancestry individuals as the LD reference. GRS of GP+M sample 20 individuals were generated for a range of MD GWAS summary statistics data association P value thresholds 21 (5.0E-8, 1.0E-5, 1.0E-4, 1.0E-3, 1.0E-2, 0.05, 0.1, 0.5). For each discovery-target pair, three outcome variables 22
were calculated. (1) The P value of case-control GRS difference from logistic regression. (2) Area under the 23 receiver operator characteristic curve using R package pROC 103 , which can be interpreted as the probability of 24 ranking a randomly chosen case higher than a randomly chosen control. (3) Odds ratio and 95% confidence 25 interval for the 2 nd to 10 th GRS deciles group compared with 1 st decile. We also used UKB PUD GWAS summary 26 statistics to calculate genetic risk score based on P value threshold 5E-8 for individuals from GERA cohort and 27 conducted out-of-sample GRS PUD prediction for GERA individuals following same analyses above. Competing interests 18 The authors declare no competing interests. 19 20 21 Data availability 22 Summary statistics are available at http://cnsgenomics.com/data.html. The data that support the findings of 23 this study are available from UK Biobank (http://www.ukbiobank.ac.uk/about-biobank-uk/). Restrictions apply 24 to the availability of these data, which were used under license for the current study (ID: 12505). Data are 25 available for bona fide researchers upon application to the UK Biobank. We also used peptic ulcer disease 26 GWAS summary statistics (https://cnsgenomics.com/data.html) from the Resource for the Genetic 27 Epidemiology Research on Adult Health and Aging (GERA: dbGaP phs000674.v2.p2) study. We used GWAS 28 summary statistics for major depression that include data from 23andMe. These data can be obtained by 29
qualified researchers under an agreement with 23andMe that protects the privacy of the 23andMe participant 30 23andMe . Researchers can perform meta-analysis of 23andMe summary statistics and the other five-cohort 31 results file, as described in Wray et al. 49 , to get major depression GWAS summary statistics (excluding UK 1 Biobank cohort). The data for generating the figures are provided in the Supplementary Materials. 2 3 All the code for the analyses in this study are at http://cnsgenomics.com/data.html. 4 For each of GORD, PUD, IBS and IBD disease (defined as index disease), we conduct competitive comorbidity analyses to test among the other three diseases which disease is more prone to be comorbid with the index disease. The disease on the left of red dashed line is the index disease and the number shows the number of cases without any comorbidity. The corresponding Venn diagram shows the number of individuals diagnosed with at least one of the other three diseases. After removing the overlapped individuals for these three diseases, we calculated the number of individuals diagnosed both with the index disease and each of the other three diseases (number outside of the Venn diagram). We then calculated the proportion of the index disease cases in the other three diseases respectively and compared them in pairs by using two-proportion Z test to conclude which disease is more prone to be comorbid with the index disease, as shown in the bottom of each Venn diagram (order represents from more prone to less prone). SNPs highlighted with green triangles are independent loci with P < 5.0E-8, corresponding to the green triangles in Panel C. The blue dots are for SNPs rs2976388 and rs687621, the only two loci associated with duodenal ulcer in a Japanese cohort 17 . rs681343 showed statistically significant in GERA PUD GWAS summary statistics, as annotated in the blue box. Schematic diagram on the right side represents the reported biological evidence supporting genes around the PUD associated loci in peptic ulcer involvement. MUC1 and FUT2 have been linked to susceptibility to Helicobacter Pylori infection and PSCA and ABO have been proposed to be associated with subsequent response after infection. CCKBR encodes cholecystokinin receptor mediating therapeutic effect for peptic ulcer treatment by reducing acid secretion and inhibiting gastrointestinal motility. The cholecystokinin receptor is also an effect-mediating target of itriglumide on phase II clinical trial for anxiety and panic disorder. Panel B. Association with GORD. SNPs highlighted with orange squares are genome-wide statistically significant (P < 5.0E-8) independent loci, which correspond to the orange squares in Panel C. DRD2 is near GORD-associated SNP rs10891491and encodes dopamine D2 receptor, which is a target for psychiatry disorders and blocking this receptors in the chemoreceptor trigger zone relieves nausea and vomiting feeling and in the gastrointestinal tract increases motility 61 , as shown in the left side of Manhattan plot for GORD. Panel C. Association with GP+M. SNPs highlighted with red diamond are independent loci with P < 5.0E-8. All the SNPs associated with GORD (highlighted with orange squares) have P < 1.0E-5 in GP+M and only 2 of 4 SNPs associated with PUD (highlighted with green triangles) are with P < 1.0E-5 in GP+M. rs2976388 is also highlighted with blue dots given the previous reported association with duodenal ulcer in a Japanese cohort. Panel D. Association with IBS+M. SNPs highlighted with red diamond are independent loci with P < 5.0E-8. The blue dot is for rs10512344 that has been reported associated with female IBS in the UKB data 20 . Figure 4A . Mendelian Randomisation (MR) results between major depression (MD) and six digestion phenotypes. The left y axis represents MD while the right y axis represents six digestion phenotypes. The arrow for each horizontal line represents the direction from exposure trait to outcome trait relative to the y-axes labels. OR and 95% CI are represented as diamond and horizontal lines taking values from x axis. Each digestive phenotype corresponds to two horizontal lines. "R" on the right side of the horizontal line represents relaxation of significance threshold to obtain more genetic instrument (Table S15 ) and the number of the SNP instruments used in analysis are shown above the diamond. The common pathological characteristics or symptoms for these phenotype-related diseases are shown on the right side (but pathological characteristics or symptoms are not limited to these locations). Figure 4B . Genetic risk score (GRS) of major depression (MD) predicts odds ratio (OR) for GP+M. GRS from MD associated SNPs with P< 0.01 were converted to deciles (1 = lowest, 10 = highest). OR and 95% confidence intervals (CI, orange diamonds and bars) relative to decile 1 were estimated using logistic regression. The blue dashed lines represent that compared with the lowest decile, the highest decile have an OR of 1.34 for GP+M related disorders, mainly gastro-oesophageal reflux disease. 
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